Skip to main content

Aethlon Medical(AEMD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.3709
Day High0.4250
Open:0.4100
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifierยฎ in Oncology
PR Newswire
Aethlon Announces Reverse Stock Split
PR Newswire
Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PR Newswire
Aethlon Medical Announces Fiscal First Quarter Financial Results and Provides Corporate Update
PR Newswire
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023
PR Newswire
Aethlon Medical Signs Collaboration Agreement with 34 Lives to Evaluate the Ability of the Hemopurifierยฎ to Expand the Utility of Unused, Donated Kidneys for Transplant
PR Newswire
Aethlon Medical Appoints Medical Device and Biomedical Executive, Nicolas Gikakis, to its Board of Directors
PR Newswire
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update
PR Newswire
Aethlon Medical to Release Fourth Quarter and Year End Financial Results and Host Conference Call on June 28, 2023
PR Newswire
Aethlon Medical Announces Investigation of the Hemopurifierยฎ for Use in Organ Transplantation
PR Newswire
Aethlon Medical to Participate in the Healthcare Virtual Conference Presented by Maxim Group and Hosted by M-Vest
PR Newswire
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
PR Newswire
Aethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifierยฎ to Treat Severe COVID-19 in India
PR Newswire
Aethlon Medical Announces Third Quarter Financial Results and Provides Corporate Update
PR Newswire
Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023
PR Newswire
Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023
PR Newswire
Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer
PR Newswire
Aethlon Medical Announces Second Quarter Financial Results and Provides Corporate Update
PR Newswire
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2022
PR Newswire
Aethlon Medical to Present at Two Investor Conferences in September
PR Newswire
Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update
PR Newswire
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022
PR Newswire
Aethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven COVID-19 Variants
PR Newswire
Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment
PR Newswire
Aethlon Medical Announces Fiscal Year End Financial Results and Provides Corporate Update

Profile

Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.